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Paraneoplastic pemphigus (PNP) is a rare and often fatal autoimmune blistering disease 
accompanied by both benign and malignant neoplasms. Usually, oral, skin, and mucosal 
lesions are the earliest manifestations shown by PNP patients. Oral ulcers are initial lesions 
in various autoimmune diseases like pemphigus, bullous pemphigoid, erythema multiforme, 
graft-versus-host, lichen planus, it does not improved despite of high-dose steroid therapy. 
We report a-35-year-old female who presented oral ulceration, lip crust and skin lesions. By 
doing several examinations, such as enzyme-linked immunosorbent assay, incisional biopsy 
with indirect immunofluorescence, she was diagnosed PNP with non-Hodgkin’s lymphoma 
on pancreas.
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INTRODUCTION
Paraneoplastic pemphigus (PNP) is a rare, autoimmune 
mucocutaneous blistering disease, frequently associat-
ed with lymphoproliferative disorders [1]. These disorders 
are typically chronic lymphocytic leukemia, lymphoma, 
Castleman’s disease, and thymoma. PNP was first reported 
by Anhalt et al. [2] in 1990. PNP accounts for 3% to 5% of 
all pemphigus cases. Without any significant difference be-
tween male and female, it arises usually in patients aged 
between 45 and 70 years [3]. PNP can affect also children 
and adolescents. In this group of patients, PNP is more fre-
quently associated with Castleman’s disease and hemato-
logic malignant disorders [4].
The usual initial manifestation is painful progressive sto-
matitis. PNP lesions exists not only the oral mucosa, but 
also esophagus, stomach, duodenum, and colon [5]. It is 
characterized by painful mucosal erosions and polymorphic 
cutaneous lesions [6]. Erythema multiforme (EM)-like or li-
chenoid eruptions, rather than blister-like lesions, are more 
commonly observed [7]. 
PNP has been considered as more resistant to medical 
therapies in comparison to other forms of pemphigus [8]. 
Corticosteroids are considered as first selected medication. 
However, these only improve the skin lesion, while mucosal 
lesion is not affected by steroid [9]. We document a case of 
PNP in a-35-year-old female who suffers from non-Hodg-
kin’s lymphoma.
CASE REPORT
A-35-year-old female presented to the Department of 
Orofacial Pain and Oral Medicine, Dental Hospital of Yonsei 
University (Seoul, Korea) complaining of painful oral ulcer-
ation happened 4 months ago (Fig. 1). The patient also had 
skin lesions on hands, feet, arms (Fig. 2), and genital lesion. 
Cutaneous eruptions occurred following mucosal lesions. 
The patient had extensive and painful oral ulceration with 
crust and spots of bleeding on lip, and multiple skin lesions 
with no pain and itching. However, the severity of skin le-
sions was much less than the oral ulcers.
Although she had already taken nonsteroidal anti-inflam-
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matory drugs and steroid prescribed from other hospitals, 
her condition was remained. In previous serological test by 
other hospitals, antinuclear antibody and human leukocyte 
antigen B51 were positive, these mean the possibility that 
she has autoimmune diseases or Behcet’s disease.
In our department, Human immunodeficiency virus and 
Hepatitis C virus test (OraQuick; OraSure Technologies, Inc., 
Bethlehem, PA, USA) was done and the result was negative. 
Additional serological test was done, including erythrocyte 
sedimentation rate, C-reactive protein, Vitamin B12, folate, 
Zinc, anti-desmoglein 1 Enzyme-linked immunosorbent as-
say (ELISA), anti-desmoglein 3 ELISA, Herpes simplex virus 
antibody (IgG, IgM). In addition, she was prescribed topical 
and systemic prednisolone, and consulted to dermatology 
for skin lesion evaluation
In department of the dermatology, an incisional biop-
sy was performed for histology. The histopathology re-
vealed lichen planus (LP), showing interface dermatitis 
with basal vacuolization. At that time, the result of serum 
anti-desmoglein 3 ELISA which was done by our depart-
ment at first visit is positive, that means the possibility of 
pemphigus. She visited our department, again. Although 
she took medicine properly and applied ointment, there is 
no improvement (Fig. 3).
These various clinical, serological, and histological results 
stand for the possibility of PNP. Also, Indirect immunofluo-
rescence (IIF) of the patient’s serum on rat bladder substrate 
showed markedly positive staining, a finding strongly asso-
ciated with PNP with a reported specificity of 83% to 100%. 
Thus, an underlying malignancy was sought, despite there 
being no symptoms or features on physical examination to 
suggest such a diagnosis
For the evaluation, chest, abdomen, pelvis computerized 
tomography (CT) were taken. CT shows splenomegaly with 
enhanced masses, possibly lymphoproliferative disease, 
such as lymphoma or Castleman’s disease (Fig. 4).
For further evaluation, she was consulted to the depart-
ment of hemato-oncology. Bone marrow biopsy did not 
Fig. 1. Oral and lip lesions at the first 
visit.
Fig. 2. Skin lesions at the first visit.
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reveal any abnormalities. Splenectomy was performed fol-
lowed by excision for histology as the cytology was sugges-
tive of a malignancy CD20+ indolent B cell non-Hodgkin 
lymphoma. The histopathology and immunohistochemistry 
confirmed that as a non-Hodgkin’s lymphoma. She has no 
family history. No metastases were identified. 
DISCUSSION
PNP is associated with benign and malignant neoplasm, 
such as non-hodgkin’s lymphoma, chronic lymphocytic 
leukemia, and Castleman’s disease. A 3% to 5% of all pem-
phigus cases are diagnosed with PNP. The age range of 
affected individuals is usually from 45 to 70 years without 
gender difference. In about 30% of all PNP, the first clinical 
manifestation leads to the detection of an occult tumor [3]. 
Clinical features of PNP are extremely polymorphous. 
PNP lesions can be detected not only on skin, but also in 
different mucosal area [2]. Especially, oral mucosa is almost 
always involved and usually the vermillion border of the 
lips is included, which resembles the oral lesion of EM [10]. 
Ulceration may involve the entire oral mucosal surface, 
such as painful stomatitis caused by massive erosion in the 
oropharynx [11]. Usually, skin lesions appear after the onset 
of mucosal lesions [12]. A single patient may present dif-
ferent types of lesions, each of which is able to evolve from 
one type to another [3,12]. Usually, oral and cutaneous le-
sions of PNP resemble those seen in pemphigus vulgaris, 
bullous pemphigoid, EM, graft versus host disease (GVHD) 
or LP [8,13].
The pathogenesis of PNP is not yet completely under-
stood. One of the proposed pathogenesis is that lymphoid 
neoplasm causes immune dysregulation, leading to auto-
antibody production against self-antigens [14]. A subse-
quent theory focuses on the initial role of desmoglein 1 and 
desmoglein 3, which are autoantigens in clinical variants 
of pemphigus. In addition, PNP produces autoantibodies 
against proteins of the plakin and cadherin families, which 
are involved in cell structure maintenance and tissue cohe-
sion. As structural components of desmosome and hemides-
mosome, their autoantibody reaction in keratin cytoskeleton 
of keratinocytes can result in the suprabasal clefting in PNP 
[15].
Fig. 4. The chest, abdomen, pelvis computerized tomography 
image, showing spenomegaly with multiple homogeneously 
enhanced masses (arrows).
Fig. 3. Intraoral photo at the second 
visit.
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The diagnostic criteria for PNP was first proposed by 
Anhalt et al. [2] with the introduction of the disease. It in-
cludes mucocutaneous blistering and ulceration as well as 
histopathological features, such as acantholytic changes of 
the epithelium and epidermis with interface dermatitis, de-
position of IgG and C3 in intercellular areas and/or along 
the basement membrane, presence of various desmoplakins 
and desmogleins in the serum which can be identified by 
ELISA. An important histological finding to diagnosis PNP 
is dyskeratosis with suprabasal acantholysis [3]. However, 
sometimes the acantholysis is difficult to find, even though 
it is important diagnostic pitfalls with other diseases as EM, 
Stevens Johnson Syndrom, GVHD, and drug reactions [16]. 
Serological testing for PNP is based primarily on the detec-
tion of anti-plakin autoantibodies including desmoplakin, 
periplakin, and envoplakin. ELISA is a useful tool to detect 
anti-desmoglein 3 and anti-desmoglein 1 autoantibodies in 
PNP, although PNP patients usually show only anti-desmo-
glein 3 antibody [17]. Direct immunofluorescence (DIF) re-
sult usually shows weak or moderate positivity in the inter-
cellular area for IgG and C3 [2]. IIF identifies autoantibodies 
directed against plakins, among which autoantibodies to 
envoplakin and periplakin are the most specific. IIF on rat 
bladder is now thought as a useful screening test for PNP 
due to the high specificity (83%) [18].
High-dose corticosteroids are still considered as a first 
line therapy of PNP [9]. PNP therapy remains challenging 
because of the rarity of the disease. Although several medi-
cal therapies have been suggested in the literature, PNP has 
been considered to be more resistant to medical therapies in 
comparison to other forms of pemphigus [19]. 
Early diagnosis of PNP is critical. When patient clinically 
presents severe and refractory oral mucosal ulceration or 
heterogeneous oral lesion including pemphigus, pemphi-
goid, LP, and EM, we should consider the possibility of PNP. 
Further evaluation should include incisional biopsy with 
DIF and anti-desmoglein ELISA. When the patient shows 
certain features include intercellular substance and base-
ment membrane staining on DIF, and suprabasal acantholy-
sis, keratinocyte necrosis and lichenoid infiltration on histo-
pathology [1,2], clinicians should consider PNP, even if the 
patient is otherwise systemically sound.
In addition, we should carefully examine the patient who 
is diagnosed with pemphigus with heterogeneous clini-
cal and/or histologic findings. Furthermore, diagnosis and 
management of PNP requires close collaboration between 
physicians, including dermatologist, oncologist, and dentist. 
Since the oral lesion of the PNP occurs in its initial stage, 
the role of dental clinicians is significant in diagnosis of 
PNP. 
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